PMC:7786642 / 20891-21827 JSON TXT

Annnotations TAB JSON ListView MergeView

Id	Subject	Object	Predicate	Lexical cue	hp_id
T7	155-167	Phenotype	denotes	hypertension	http://purl.obolibrary.org/obo/HP_0000822
T8	169-206	Phenotype	denotes	chronic obstructive pulmonary disease	http://purl.obolibrary.org/obo/HP_0006510
T9	208-212	Phenotype	denotes	COPD	http://purl.obolibrary.org/obo/HP_0006510

Id	Subject	Object	Predicate	Lexical cue	tao:has_database_id
191	71-74	Chemical	denotes	NO2
192	673-676	Chemical	denotes	phe	MESH:D010649
193	736-739	Chemical	denotes	NO2
194	78-86	Disease	denotes	COVID-19	MESH:C000657245
195	87-96	Disease	denotes	mortality	MESH:D003643
196	155-167	Disease	denotes	hypertension	MESH:D006973
197	169-206	Disease	denotes	chronic obstructive pulmonary disease	MESH:D029424
198	208-212	Disease	denotes	COPD	MESH:D029424
199	218-226	Disease	denotes	diabetes	MESH:D003920
200	300-308	Disease	denotes	COVID-19	MESH:C000657245
201	309-318	Disease	denotes	mortality	MESH:D003643

Id	Subject	Object	Predicate	Lexical cue
T179	0-142	Sentence	denotes	In a post-hoc analysis we investigated if the evidence of an effect of NO2 on COVID-19 mortality can be attributed to pre-existing conditions.
T180	143-528	Sentence	denotes	We selected hypertension, chronic obstructive pulmonary disease (COPD) and diabetes, because of 1) indications of previous literature that they increase the COVID-19 mortality risk (Williamson et al., 2020, Yang et al., 2020), 2) previous literature that suggest an effect with long-term exposure NO2 (Balti et al., 2014, Cai et al., 2016, Zhang et al., 2018) and 3) data availability.
T181	529-721	Sentence	denotes	We retrieved prevalence data for these pre-existing conditions from PHE available at the GP practice level during 2018–2019 (https://fingertips.phe.org.uk/), Supplemental Material Fig. S30-32.
T182	722-936	Sentence	denotes	The effect of NO2 remains similar, 0.6% (95% CrI: −0.1%, 1.3%) with the posterior probability being 0.94 whereas the spatial relative risk highlights the same geographical locations, Supplemental Material Fig. S33.